Investment Thesis
Agilon Health exhibits deteriorating operational performance with revenue declining 2.1% YoY and net income plummeting 50.4% YoY, while operating margins have compressed to a critically thin 0.3%. Despite a fortress balance sheet with minimal leverage and strong ROE of 27%, the company's cash generation is insufficient and liquidity is tightening, indicating fundamental business model stress in a competitive healthcare services environment.
Strengths
- Minimal financial leverage with 0.08x debt-to-equity ratio and only $15.3M long-term debt
- Strong return on equity of 27.0% demonstrates capital efficiency despite profitability pressures
- Positive free cash flow generation of $20.6M and substantial cash reserves of $140.0M provide runway for restructuring
Risks
- Revenue contraction of 2.1% YoY combined with 50.4% net income decline signals severe operational deterioration and margin compression
- Operating margin of 0.3% is unsustainably thin, leaving no cushion for adverse developments; company is barely operationally profitable
- Tight current ratio of 1.04x and FCF margin of only 1.5% indicate constrained liquidity and inadequate cash generation relative to operational needs
Key Metrics to Watch
- Quarterly revenue trend and growth stabilization vs. continued contraction
- Operating margin recovery; profitability sustainability at current 3.4% net margin levels
- Free cash flow conversion ratio and cash burn rate relative to $140M cash reserve
Financial Metrics
Revenue
1.4B
Net Income
48.9M
EPS (Diluted)
$2.94
Free Cash Flow
20.6M
Total Assets
1.5B
Cash
140.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
0.3%
Net Margin
3.4%
ROE
27.0%
ROA
3.3%
FCF Margin
1.5%
Balance Sheet & Liquidity
Current Ratio
1.04x
Quick Ratio
1.04x
Debt/Equity
0.08x
Debt/Assets
87.9%
Interest Coverage
3.11x
Long-term Debt
15.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T08:57:41.399724 |
Data as of: 2026-03-31 |
Powered by Claude AI